• Cadenza Bio

  Participated · Seed · Dec 2023

  Cadenza Bio is developing highly selective Estrogen Receptor β (ERβ) targeting small-molecule compounds aimed at promoting remyelination for patients with Multiple Sclerosis. The company intends to use its recent financing to advance therapeutic drug development programs focused on remyelination. Cadenza holds an exclusive license to technology originating from an academic collaboration between researchers at the University of Illinois Urbana‑Champaign and the University of California, Riverside. Its programs were launched in 2022 through a partnership between SmartHealth Catalyzer (Chicago) and Ascend BioVentures (Oklahoma City). The company notes partial prior funding from the National Multiple Sclerosis Society’s Fast Forward commercial research program. Cadenza is led by CEO Carol Curtis and is based in Oklahoma City, OK.

• Recuro Health

  Participated · Series A · Aug 2021

  Recuro Health offers a Digital Medical Home that integrates diagnostic-enabled virtual primary care, virtual behavioral health, at-home lab testing, and genomics alongside care navigation, pharmacy, and care management. The platform combines advanced science, data, at-home diagnostics and targeted genomics (including cancer screening and pharmacogenomics) to inform integrated care. Recuro positions its service as proactive and personalized, aiming to shift care from reactive, disease-focused models to preventive population health. The company plans to use new capital to advance and scale its Digital Medical Home and next-generation digital care services. Its solutions are available nationwide and are used by millions of members. Michael Gorton is CEO and founder, and the company highlights capabilities such as data analytics, quality, and guided referrals. Recuro Health operates a virtual health platform called the Digital Medical Home, providing a curated suite of digital solutions including primary care, behavioral health, at-home testing, and genetic screening. The platform is fully customizable to meet the needs of specific populations and enables patients to engage with physicians, receive personalized care, and monitor health remotely. Recuro serves payers, employers, and providers and positions itself to lower costs while improving access and outcomes as care shifts from traditional in-person settings to wherever patients and data are located. The company launched in March 2021 and is led by founder and CEO Michael Gorton. Recuro announced a convertible note financing co-led by ARCH Venture Partners and Cortado Ventures to fund its ongoing acquisition strategy and support continued growth. Cortado’s involvement marks its third investment in the company, signaling continued backer support. Recuro Health operates a customizable virtual health platform that bundles digital solutions from primary care and behavioral health to at-home testing and genetic screening. Its platform is designed to support payers, employers and providers and to create a personalized, holistic digital medical home that enables population-health and outcomes-focused care. Since launching in March 2021, Recuro has developed offerings including a widely adopted COVID-19 rapid testing solution used by employers and government customers. The company says its solutions enable earlier interventions, supplement in-person care, and provide detailed member health mosaics for risk stratification and diagnostics. Recuro plans to use the Series A proceeds to execute an acquisition strategy, expand marketing, and further build on growth since launch. Financially, Recuro announced a $15 million Series A led by ARCH Venture Partners with follow-on support from seed investors OLSF Ventures, Cortado Ventures, 1843 Capital and Sage Venture Partners. Recuro Health offers an integrated digital health platform that combines digital health tools with a patient-centered medical home, leveraging analytics and services to support patients across their entire health journeys. The company provides digital and virtual services that aggregate data to direct users to effective and efficient offerings, and evaluates outcomes and compliance to generate appropriate referrals and recommendations. Recuro says it is focused on empowering patients with tools, education and guidance to live healthier, longer and happier lives. Leadership includes Michael Gorton, founding CEO of Teladoc, alongside Teladoc's original CTO and marketing team, and additions such as Jay Sanders, MD. The company is building infrastructure and partnerships to support care delivery in every setting and to minimize the need for acute, episodic care. Recuro serves employers, providers and managed care organizations and plans to follow its current close with a larger funding round to accelerate growth.

• Sway Medical

  Led · Series A · Sep 2020

  Sway Medical develops mobile software for neurological assessment, offering patented tests that leverage the accuracy of sensors built into any mobile device. Its FDA-cleared testing platform allows users to test balance and cognitive performance in the clinic or remotely on any mobile device. The company is an MDSAP-certified medical device manufacturer with regulatory clearances in the United States, Canada, the European Union and Australia. Founded in 2011 by CEO Chase Curtiss and based in Tulsa, Oklahoma, Sway intends to use the Series A proceeds to expand in Tulsa by adding to its product team and sales organization. It closed a $4.2M Series A financing to fund that expansion. The company's product and international clearances position it for broader clinical and remote-use adoption. Sway Medical develops Sway Balance, a mobile medical diagnostics app that uses motion sensors in smartphones to perform clinical-grade balance testing. Led by founder and CEO Chase Curtiss, the app provides a mobile alternative to standard pen-and-paper diagnostic tests and can show whether a person has probably suffered a concussion. Sway Balance is available for medical professionals and distributors on the Apple iOS App Store and gathers evidence in moments. Its technology is currently used for instantaneous clinical management of concussions in athletes aged 10 through adulthood. Future versions are planned to assist monitoring patient outcomes in physical therapy, orthopedic and primary care practices, senior living facilities, and worksite medical clinics. The company also announced a strategic partnership with ImPACT Applications to create new tools and expand distribution at sporting events. Sway Medical completed a $750k tranche of its Series A and has raised $1.325m in total funding to date. Sway Medical Technologies is a Tulsa, OK-based mobile software company founded in 2011 and led by CEO Chase Curtiss. It develops medical-grade mobile applications to monitor patient outcomes in orthopedics, geriatrics, and pharmacology, and to provide on-field assessment of concussion symptoms in athletes. Its initial product, Sway Balance, is an FDA-cleared balance system that uses existing hardware in mobile devices for stability assessment. The company recently closed $700K in funding, with $300K invested by the OKAngel Sidecar Fund, managed by i2E, Inc., and the remainder from Oklahoma-based angel investors. Sway Medical's software-focused approach centers on leveraging mobile devices for clinical and field assessments. The OKAngel Sidecar Fund is one of three Accelerate Oklahoma! investment vehicles created in 2011 by i2E in partnership with the Oklahoma Department of Commerce and the U.S. Treasury State Small Business Credit Initiative.

• Otologic Pharmaceutics

  Participated · Series A · Apr 2014

  Otologic Pharmaceutics is a development-stage biopharmaceutical company based in Oklahoma City focused on developing and commercializing novel pharmacological approaches to treat hearing disorders. Its lead product candidate is referenced as NHPN-1010, and the article also identifies HPN1010 as an oral treatment for Acute Hearing Loss. The company plans to advance its lead candidate into clinical development, with HPN1010 scheduled to enter clinical trials in 2014. Otologic intends to use the proceeds from its recent financing to advance development of NHPN-1010. The company underwent executive leadership change in conjunction with the financing: Clayton I. Duncan of Accele Biopharma was named CEO, replacing David Karlman. No operating metrics (revenue/users) were disclosed in the article. Otologic Pharmaceutics is a development-stage pharmaceutical company based in Oklahoma City focused on commercializing novel pharmacological solutions for hearing health. Its core work centers on advancing therapeutics for inner ear disorders and other hearing-health applications. The company has in-licensed a portfolio of 19 patents that underpin its programs. A team of nationally and internationally recognized inner ear medicine experts, biomedical research scientists and business leaders supports its development and commercialization efforts. Otologic recently closed a financing round of undisclosed amount led by the OCAST Technology Business Finance Program with participation from INTEGRIS Health and the Oklahoma Medical Foundation. The company says the funding will enable it to advance its therapeutics and continue building the business.

• AliveCor

  Participated · Series B · Jun 2012

  AliveCor is a Mountain View, California-based provider of FDA-cleared personal electrocardiogram (ECG) technology solutions led by CEO Priya Abani. Its core consumer hardware includes the clinically validated KardiaMobile device and the multi-lead KardiaMobile 6L, which detects atrial fibrillation, bradycardia, tachycardia and various ECG rhythms. The company offers the Kardia AI-enabled platform to assist patients and clinicians in the efficient detection of atrial fibrillation. For enterprise customers AliveCor provides an enterprise platform including KardiaComplete for payors, employers, and health systems enabling front-end and back-end integration. AliveCor also operates a digital health subscription, KardiaCare, with more than 130,000 members offering advanced features to understand and manage heart health. The company intends to use new funding to expand its development efforts. AliveCor, based in Mountain View, CA and led by CEO Priya Abani, develops AI-based personal ECG technology and enterprise cardiology solutions. Its FDA-cleared KardiaMobile device is a clinically validated personal ECG that provides instant detection of atrial fibrillation, bradycardia, tachycardia, and normal heart rhythm. The company’s enterprise platform enables third-party providers to manage patients’ heart conditions with front-end and back-end integration to AliveCor technologies. To date, AliveCor’s products have served more than one million customers and recorded over 85 million ECGs. The company says it will use recent funding to accelerate growth of its remote cardiology platform domestically and around the world. Kardia aids patients and clinicians in the early detection of atrial fibrillation, a common arrhythmia associated with elevated stroke risk. AliveCor develops single- and six-lead smartphone ECG devices and AI-based interpretation software for consumer and point-of-care use. Its latest hardware, KardiaMobile 6L, launched in June and captures six perspectives by adding a third contact point. The company also secured FDA clearance for KardiaAI, an update for KardiaMobile and KardiaStation. AliveCor recently disclosed a new $5.78M infusion of capital and has a prior $30M round from 2017 led by Mayo Clinic and Omron Healthcare. Management has not announced how the new funds will be allocated. The business faces competition from entrants such as the Apple Watch’s ECG feature and has previously discontinued its KardiaBand for Apple Watch. AliveCor develops AI-enabled solutions to improve cardiac care, notably KardiaMobile and KardiaBand. KardiaMobile is an FDA-cleared product that instantly detects atrial fibrillation and normal sinus rhythm and is used worldwide for accurate ECG recordings. Paired with the Kardia app, KardiaMobile and KardiaBand provide instant analysis for detecting atrial fibrillation and normal sinus rhythm. Kardia is an AI-enabled platform for clinicians to manage patients for early detection of atrial fibrillation. The company said it will use new capital to support growth as well as research and development efforts. AliveCor is a Mountain View, California-based provider of FDA-cleared mobile electrocardiogram technology. Led by CEO Vic Gundotra, the company has launched Kardia Pro, an artificial intelligence-enabled platform that helps doctors monitor patients for early detection of atrial fibrillation. Kardia Pro tracks physiology measures such as weight, activity and blood pressure and creates a personal heart profile for each user, enabling user identification. AliveCor raised $30M in a Series D funding round led by Omron Healthcare, with participation from Mayo Clinic and existing inside investors. The company will use the capital to accelerate innovations in heart health and to continue expansion of the business. Its technology focuses on early detection of atrial fibrillation, the most common cardiac arrhythmia that increases stroke risk.

No current team members are available.